Anika Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit)
Anika Therapeutics, Inc. (ANIK) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-03
- Anika Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- Anika Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Anika Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $1.58M.
- Anika Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$904.00K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-03 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-03 | |
| 2023-12-31 | $1.58M 10-K · filed 2026-03-03 | -$5.04M 10-K · filed 2024-03-15 |
| 2022-12-31 | -$904.00K 10-K · filed 2025-03-17 | -$3.24M 10-K · filed 2023-03-16 |
| 2021-12-31 | -$553.00K 10-K · filed 2024-03-15 | |
| 2020-12-31 | -$1.98M 10-K · filed 2023-03-16 | |
| 2019-12-31 | $1.09M 10-K · filed 2022-03-11 | |
| 2018-12-31 | -$992.00K 10-K/A · filed 2021-04-26 | |
| 2017-12-31 | -$426.00K 10-K · filed 2020-03-06 | |
| 2016-12-31 | -$70.00K 10-K · filed 2019-02-27 | |
| 2015-12-31 | -$370.00K 10-K · filed 2018-02-27 | |
| 2014-12-31 | $1.15M 10-K · filed 2017-02-24 | $1.15M 10-K · filed 2015-03-13 |
| 2013-12-31 | $2.38M 10-K · filed 2016-03-10 | $2.37M 10-K · filed 2014-03-13 |
| 2012-12-31 | $776.49K 10-K · filed 2015-03-13 | |
| 2011-12-31 | $1.91M 10-K · filed 2014-03-13 | |
| 2010-12-31 | $2.83M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |